The assessment of microalbuminuria (MAU) is an important prognostic indicator for CVD and renal damage and should be an element in an overall cardiometabolic fitness approach.
Angiotensin receptor blockers, primarily known as safe and effective antihypertensive agents, are not generally recognized as having a dramatic dose response effect — on blood pressure, that is. But these agents do more than lower BP. New data from SMART (SupraMaximal Doses of Atacand and Renal Therapy) show surprising effects on proteinuria.
